GLP-1 medications work by mimicking glucagon-like peptide-1, a hormone that signals fullness and reduces hunger
This helps protect lean muscle, improves fullness, and supports steady fat loss
While recent case reports have suggested a possible link with GLP-1RA therapy and ION risk (particularly non-arteritic anterior ischaemic optic neuropathy), large-scale analyses examining formulation-specific risk have been lacking
Approval status here changes faster than anywhere else on the list, so treat this as a snapshot
6 Several of these drugs, such as Wegovy and Zepbound, were approved for use as a treatment for obesity, obstructive sleep apnea, heart attack or stroke prevention in those who have already experienced a cardiovascular event